Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GLA | P06280 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630102 | 0.84 | KDM4E (0.62) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14716159 | 0.84 | KDM4E (0.65) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14728485 | 0.82 | MAPK1 (0.61) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14728340 | 0.80 | MAPK1 (0.56) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14728343 | 0.80 | MAPK1 (0.56) | KDM4ENPSR1MAPTLMNAKMT2A | |
| SCHEMBL14728394 | 0.78 | MAPK1 (0.54) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14728269 | 0.78 | PDE4B (0.40) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14728611 | 0.78 | MAPK1 (0.48) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14728254 | 0.77 | MAPT (0.52) | KDM4ENPSR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14748400 | 0.77 | MAPT (0.33) | KDM4ENPSR1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2565194-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | PDE4B, PDE4A, PDE4C | KDM4E 586/4885NPSR1 2690/4885MAPT 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.